Severe influenza pneumonia
Infection · Respiratory
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
Primary viral pneumonia or influenza with secondary bacterial infection causing severe hypoxaemic respiratory failure, particularly in the elderly, pregnant, immunocompromised or those with chronic disease.
Red flags
- Rapidly progressive hypoxaemia despite oxygen
- Haemodynamic instability / secondary sepsis
- Haemoptysis or cavitation (necrotising staphylococcal infection)
- Pregnancy or immunosuppression
Assessment
Differential diagnosis
- COVID-19 or other viral pneumonia
- Bacterial community-acquired pneumonia
- Secondary bacterial pneumonia (S. aureus, S. pneumoniae)
- ARDS from other cause
- Cardiogenic pulmonary oedema
Investigations
- Nasopharyngeal swab for influenza PCR
- CXR (bilateral infiltrates)
- ABG / SpO2
- FBC, U&E, CRP, LFTs
- Blood cultures and pneumococcal/atypical screen if secondary infection suspected
Management
- Isolate with droplet precautions
- Give controlled oxygen; escalate to HFNO/NIV/ventilation as needed
- Start antiviral therapy early (best within 48 h but give if severe regardless of onset)
- Cover secondary bacterial infection empirically if clinical/radiological suspicion (including MRSA in severe cases)
- Support organ function and consider ICU for refractory hypoxaemia
- Consider ECMO referral for refractory ARDS
Drugs & doses
Oseltamivir (or IV/inhaled zanamivir if enteral route unavailable)
Empirical antibiotics for secondary bacterial pneumonia if suspected
Oxygen / respiratory support
Antipyretics / supportive care
Disposition
Admit; HDU/ICU for respiratory support; ECMO centre referral if refractory.
Complications & pitfalls
- ARDS
- Secondary bacterial pneumonia
- Myocarditis / rhabdomyolysis
- Multi-organ failure
Exam pearls
- Do not delay antivirals for the swab result in severe or high-risk disease
- Necrotising pneumonia with influenza suggests Panton-Valentine leukocidin S. aureus - consider anti-toxin cover
- Neuraminidase inhibitors still benefit late presentation when critically ill
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.